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Background: In schizophrenia, medication adherence is critical to achieve better patient outcomes and to avoid
relapses, which are responsible for a significant proportion of total healthcare costs for this chronic illness. The aim
of this study was to assess the cost-effectiveness of olanzapine long-acting injection (OLAI) compared with
risperidone long-acting injection (RLAI) in patients with schizophrenia in Spain.
Methods: A discrete event simulation (DES) model was developed from a Spanish healthcare system perspective to
estimate clinical and economic outcomes for patients with schizophrenia over a five-year period. Patients who had
earlier responded to oral medication and have a history of relapse due to adherence problems were considered.
Identical model populations were treated with either OLAI or RLAI. In the absence of a head-to-head clinical trial,
discontinuation and relapse rates were obtained from open-label studies. The model accounted for age, gender,
risks of relapse and discontinuation, relapse management, hospitalization, treatment switching and adverse events.
Direct medical costs for the year 2011 and outcomes including relapse avoided, life years (LYs), and quality-adjusted
life years (QALYs) were discounted at a rate of 3%.
Results: When comparing RLAI and OLAI, the model predicts that OLAI would decrease 5-year costs by €2,940
(Standard Deviation between replications 300.83), and result in a QALY and LY gains of 0.07 (SD 0.019) and 0.04
(SD 0.025), respectively. Patients on OLAI had fewer relapses compared to RLAI (1.392 [SD 0.035] vs. 1.815 [SD 0.035])
and fewer discontinuations (1.222 [SD 0.031] vs. 1.710 [SD 0.039]). Sensitivity analysis indicated that the study was
robust and conclusions were largely unaffected by changes in a wide range of parameters.
Conclusions: The present evaluation results in OLAI being dominant over RLAI, meaning that OLAI represents a
more effective and less costly alternative compared to RLAI in the treatment of patients with schizophrenia in the
Spanish setting.
Keywords: Cost-effectiveness analysis, Discrete event simulation, Economic model, Long-acting olanzapine,
Long-acting risperidone, Antipsychotic, Schizophrenia, SpainBackground
Schizophrenia is a chronic illness associated with consid-
erable clinical, social, and economic consequences. Schizo-
phrenia results in enduring symptoms and prolonged
functional impairment. Estimates of the prevalence of
schizophrenia in Spain, calculated from epidemiological
and demographic data, indicated a mean prevalence of* Correspondence: dilla_tatiana@lilly.com
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unless otherwise stated.3.0 per 1000 inhabitants per year for men and 2.86 per
1000 for women per year [1]. Suboptimal adherence to
prescribed treatment is a prime driver of relapses, rehospi-
talisation, and persistence of psychotic symptoms. Non-
compliance rates vary from 41.2 to 49.5% in patients with
schizophrenia [2,3].
Schizophrenia is an extremely resource-intensive dis-
order. The costs of relapses and rehospitalisation have
significant effects on healthcare budgets [4-7]. Direct. This is an Open Access article distributed under the terms of the Creative
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associated with schizophrenia accounts for about 2.7% of
total public healthcare expenditure in 2002 [7]. The total
costs of schizophrenia in 2002 in Spain were estimated at
€1,971 million with direct medical costs (hospitalisation,
outpatients consultation and drug costs) contributing sig-
nificantly (53%) to the total cost [7,8]. The Schizophrenia
Outpatient Health Outcomes (SOHO) study, using unit
costs based on UK Department of Health data and inflated
to 2005 prices showed that the cost of managing relapse
in patients with schizophrenia is about £14,055 [9]. Several
studies confirm that schizophrenia imposes a high burden
on national health-care costs [10-13].
Pharmacological management of schizophrenia relies
greatly on antipsychotic drugs. Olanzapine pamoate mono-
hydrate is a long-acting intramuscular depot formulation
(OLAI) indicated for the maintenance treatment of adult
patients with schizophrenia sufficiently stabilised during
acute treatment with oral olanzapine [14]. Risperidone
long-acting injection (RLAI) is a combination of extended
release microspheres for injection and diluent for paren-
teral use; it is indicated for the maintenance treatment of
schizophrenia in patients currently stabilised with oral
antipsychotics [15].
Long-acting injectable antipsychotics may be used as
an alternative to oral medication therapy in the case of
patients with schizophrenia for whom adherence is a
clinically significant problem [16].
The general safety and tolerability profile for OLAI is
similar to that for oral olanzapine [17]. However, during
the pre-marketing clinical trial program, a small propor-
tion of OLAI recipients experienced signs and symptoms
consistent with olanzapine overdose described as “post-
injection syndrome”. The clinical features of post-injection
syndrome included sedation, and/or delirium [18,19]. It
has been suggested that the syndrome may be a result
of unintended partial intravascular injection or blood
vessel injury during the injection [18,19]. This syndrome
occurred in <0.1% of injections and approximately 2% of
patients [14]. According to the OLAI (Zypadhera®) SPC,
an observation period of 3 hours is required following
administration of OLAI [14].
The rising cost of health care has increased the need
to demonstrate that health care interventions are not
only clinically effective, but are also cost-effective. In
terms of cost of therapy, psychotic disorders, especially
schizophrenia, are considered the most expensive in terms
of costs of care per patient [20]. A large part of the cost of
managing patients with schizophrenia, based on cost of
illness data, stems from short-term hospitalizations and
long-term institutional or sheltered living care [20]. Cost
data from regulatory clinical trials are generally limited
because of the strict modifications made in the practice
environment so that the resulting resource use does notreflect the reality of the real world [21]. Economic models
can be used to test a wide range of scenarios and strategies
to identify the most efficient and equitable allocation of
resources [21]. Amongst various economic models, the
discrete event simulation model provides a more natural
way to simulate clinical reality although requiring more
data. The natural time-dependent characteristics of schizo-
phrenia and its progression makes it suitable for using a
DES model because it is flexible and represents multiple
factors simultaneously [22,23]. Earlier studies using the
discrete event simulation (DES) economic model concluded
that treating schizophrenia with an atypical antipsychotic
agent is cost-effective compared with conventional antipsy-
chotics and is associated with improved quality-adjusted
health over a 5-year period [24]. Using a 1-year micro-
simulation economic decision model that evaluated the
cost-effectiveness of OLAI compared with alternative anti-
psychotic agents it was found that OLAI is a cost-effective
alternative to oral olanzapine and long-acting injection
formulations of risperidone and other antipsychotics
for the treatment of non-adherent and partially adherent
patients with schizophrenia within the United States
healthcare system [25].
With a view to determine the cost-effectiveness of
OLAI within the Spanish healthcare environment, the
present evaluation compares the cost-effectiveness of OLAI
versus RLAI. A DES model was developed using relapse
and discontinuation rates obtained from indirect com-
parison of clinical trials and published literature within
the perspective of the Spanish healthcare system. The
DES model was designed to compare OLAI with the
commercially available long-acting second-generation
injectable antipsychotic, RLAI, in the management of
patients with schizophrenia.Methods
Decision trees and Markov models have been widely used
in pharmacoeconomic evaluations [26,27]. However, as
with all methodologies, these models have many limita-
tions, inherent but inadequate assumptions, and lack
the flexibility required to represent appropriately clinical
reality [27]. To overcome these limitations in order to
accurately capture all of the relevant interdependencies of
this chronic, highly heterogeneous disease with limited
long-term follow-up data [24] as well as having access to
the patient’s differences, individual memory and history,
the method of choice was discrete event simulation (DES).
The DES model exhibits flexibility in handling perspec-
tives and structural variations with few restrictions. The
model closely replicates the natural course of the disease
by incorporating multiple factors simultaneously and thus
simulating the real-world patient management environ-
ment [22-24].
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The DES economic model is a patient-level simulation
model based on the ARENA® simulation software (Rockwell
Automation, Wexford, Pennsylvania, USA). Data entries
were made using Microsoft® Excel (Microsoft Corporation,
Redmond, Washington, USA). Data were automatically
transferred to the ARENA® model. The model generated
outputs and results in Microsoft® Excel. The DES model
was designed for the present analysis to evaluate the cost-
effectiveness of OLAI versus RLAI. It was created around
the central theme of relapse and factors influencing the
event, with treatment discontinuation regarded as key in
the present economic evaluation (Figure 1). The rate of
hospitalisation was adopted as a proxy for relapse rates and
assumed that all patients entering the model started with
zero relapses. Based on attributes of age, gender and back-
ground life expectancy, the model created a population of
patients who were thereafter cloned (copied) to make it
possible to have identical patients in both treatment arms
which reduces nuisance variance in the outcomes.
Chronologically, the model recorded all events experi-
enced by patients. These included events such as drug
administration, adverse events, remissions, relapses, treat-
ment discontinuations, or death, with costs, life years
and benefits being accumulated. When a patient relapsed
and was hospitalised, the physician had the choice of
continuing the same treatment or switching to another.
Adverse events created an opportunity for the patient
to initiate a doctor visit for evaluation and treatment.
Patients not opting to initiate a doctor visit due to an
adverse event remained on the same drug but had the
potential for discontinuing from the drug. The model
had the ability to differentiate between suicide (which can
only happen off-treatment) and background mortality.
Figure 2 provides a flowchart describing the discrete-
event simulation model build for the comparison of
OLAI vs. RLAI.Figure 1 Factors influencing the Discrete-Event-Simulation model stru
the possibility of death from natural causes.The model setting
The time horizon for the model is 5 years. A discount rate
of 3% was adopted for both costs and benefits in accord-
ance with recommendations for the Spanish setting [28].
Patient characteristics were taken from patients recruited
to the UK SCAP, an observational study with two years of
follow up [29]. In the case of patients assigned to OLAI,
the model assigned for costs associated with observing
patients in the post-injection period based on a nurse visit
plus 3 hours of observation time for a group of 8 patients
in accordance with an expert panel. Model inputs and
sources of information are summarised in Table 1.
The model assumed that the appropriate maintenance
dose of OLAI would correspond to oral doses of olanza-
pine 10 mg/day (the World Health Organization (WHO)
defined daily dose for OLZ is 10 mg [34]). In order to
achieve this maintenance dose (equivalent to 300 mg/
4 weeks), the corresponding starting dose for OLAI is
405 mg/4 weeks (Table 2). Because oral supplementation
is not needed with OLAI, the model did not include oral
OLZ in the model. The model assumption for RLAI
dose was 37.5 mg administered every 14 days (the World
Health Organization (WHO) defined daily dose for
risperidone depot is 2.7 mg [35]). The suggested starting
dose for RLAI is 25 mg/2 weeks (the lowest effective
dose) increasing to a maximum (in-label dose) of 50 mg/
2 weeks. The 37.5 mg/2 week dose is based on the
mid-range dose (Table 2). Consistent with RLAI SPC,
patients starting on RLAI receive 21 days of oral risperi-
done supplementation [RLAI SPC] at an average dose
of 2.0 mg/day, according to expert opinion and clinical
practice [15,36]. Scheduled administration visits matched
the dosage schedule for OLAI and RLAI.
Costs and outcome measures
The model includes the costs associated with treatment
and concomitant medications, routine management andcture. NB: Although not diagramatically depicted, the model includes
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Figure 2 Flowchart of the discrete-event-simulation model.
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lapse. Outcomes following treatment with OLAI or
RLAI or discontinuation of treatment were captured by
the model. These included clinical data, cost details,
treatment discontinuation rates, relapses, QALYs, LYs,
adverse events, death, utilisation of healthcare resources,
and direct costs. The model used hospitalisation as a
surrogate for relapse. Concomitant medications used byTable 1 Resource and costing: data sources (updated to 2011
Data
Annualised cost of outpatient care (based on Spanish data from 2002)
Inpatient cost of relapse management based on 2000 Spanish data
Outpatient cost of relapse management based on 2000 Spanish data
(42.94% of inpatient cost)
Cost of switching treatment (assumed at three times the routine
cost of schizophrenia management = 3 × €5.64)
Cost associated with post-injection syndrome management, assuming
3 days of additional inpatient hospitalisation (€157.00), one additional
day in an emergency psychiatric ward (€107.90) and one additional
visit to a psychiatrist (€62.10) = €327.00 based on 2005 costs
Cost of administration: OLAI, based on a nurse visit cost of €24.56
plus 3 hours observation time for a group of 8 patients at €10.21
Cost of administration: RLAI based on a nurse visit cost of €24.56patients generally included anti-depressants, anxiolytics/
hypnotics, mood stabilisers, and anticholinergics (Table 3).
The outputs of the model are the predicted incremental
costs (expressed in € per patient), relapses avoided, the
effects (expressed in QALYs and LYs per patient), and the
incremental cost-effectiveness ratios (ICERs). Costs and
benefits were both discounted at 3% annually in accord-
ance with Spanish guidelines [28]. The ICER is defined asprices)
Cost (€) Source
2058.60 Bobes et al., 2004 [30]
4226.91 Peiró et al., [31]
884.38 Peiró et al., [31]
16.92/day Bobes et al., 2004 [30]
NICE (2009) [32]
368.53 Bernardo et al., 2006 [33]
34.77 http://www.oblikue.com/bddcostes/
24.56 http://www.oblikue.com/bddcostes/
Table 2 Dose and schedule of drug administration
Treatment Dose and frequency of administration
Olanzapine long-acting injection (OLAI) Starting dose: 405 mg every 4 weeks (cost per day of treatment = €10.69).
Maintenance dose 300 mg every 4 weeks (cost per day of treatment = €8.32).
Risperidone long-acting injection (RLAI) 37.5 mg every 14 days. Cost per day of treatment = €8.91
For the first 21 days, patients received additional generic oral risperidone
at an average dose of 2.0 mg/day at a cost of €0.103/mg
Cost derived from Colleges of Pharmacists Spanish Council. [Official Medicines Catalog]. 2010; https://botplusweb.portalfarma.com/. Accessed April, 2011. Drug
costs expressed in ex-factory price +4% VAT.
Table 4 Costs of therapy over a 5-year time horizon
Cost particulars OLAI (€) RLAI (€)
Mean SD Mean SD
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change in effects of the intervention. It represents the add-
itional cost of one unit of health outcome gained by a
treatment versus the next best alternative. In the Spanish
healthcare environment, an ICER of €30,000/QALY gained
is considered an acceptable threshold of cost effectiveness
[37]. Published medical literature and a clinical expert
panel were used to develop baseline model assumptions.
Data sources
The present model utilised several resource and costing
data sources (Table 1) as well as a number of clinical and
cost-effectiveness studies to inform patient characteristics
and data on adverse events, discontinuation rates, and
relapses [38-42]. In the absence of a head-to-head clinical
trial, pooled discontinuation and relapse rates were ob-
tained from long-term open-label studies weigthed for
different sample size [19,38,39,41]. OLAI is given once a
month and RLAI twice a month. The estimation of
the daily cost of therapy was based on the ex-factory
prices +4% VAT in Spain. The cost of therapy included
direct costs such as medications (including any concomi-
tant medication used), administration, cost per relapse/
hospitalisation, specialist visits, including psychiatric con-
sult (Table 4). The SOHO database [43,44] was used to
derive the tariffs for base utility associated with no relapse,
the associated tariffs following relapse, and the utility
tariffs associated with the occurrence of adverse events
(Tables 5 and 6). In the absence of available data, it was
assumed that the utility tariffs for sedation or drowsi-
ness and post-injection syndrome are equivalent to that
of sexual dysfunction, which has the highest decrement






Anti-depressants € 0.65 Identified during clinical advisory
panels for the SOHO study and are
considered to be the most used
for patients with schizophrenia
Anxiolytics/Hypnotics € 0.10
Mood stabilisers € 0.62
Anticholinergics € 0.07
Cost derived from Colleges of Pharmacists Spanish Council. [Official Medicines
Catalog]. 2010; https://botplusweb.portalfarma.com/. Accessed April, 2011.
Drug costs expressed in ex-factory price +4% VAT.risperidone [Table 7] were based on published reports re-
garding weight gain, extra-pyramidal symptoms, somno-
lence, sexual dysfunction, tardive dyskinesia, suicide and
post-injection syndrome [14,18,19,40,41,45-47]. For the
present study, the risk of post-injection syndrome was set
at 2% of patients [14,48].Statistics
The base case analysis used a 5-year time horizon because
it was considered adequate for recording progressive events
and changes in patients’ histories without compromising
the predictive power of the model [23]. Although the base
case model setting was a 5-year time horizon, the flexibility
available in the model permitted sensitivity analyses over a
varying time horizon from 1 year to 30 years. The starting
patient population for the model was 1,000 patients per
treatment run for 100 replications per scenario. However,
the probabilistic sensitivity analysis (PSA) encompassed 100
sets of 10 replications (also with 1,000 patients per treat-
ment) where the relapse risks per drug and discontinuation
hazards are using uniform distributions ±30%, adverse
events- and relapse relative risks are using beta distribu-
tions, the costs are using gamma distributions and the
relapse utilities are varied using beta distributions. The
costs and projected mean LYs and QALYs are reported
as discounted outcomes.Drug costa 16152.18 71.50 16676.88 82.52
Administration cost 1949.85 13.21 2430.71 21.77
Cost per relapse/hospitalisationb 6860.26 169.61 8955.42 173.35
Other costsc 9047.91 41.76 8886.87 44.14
Total cost per patient 34010.21 207.83 36949.88 251.45
(The Mean and Std Dev are outcomes of the model run over 5 years with
100 replications).
aDrug cost includes cost of study drug and concomitant medications.
bSince the study assumed hospitalisation as proxy for relapse.
cOther costs include specialist visits and other medical costs (i.e. routine
management, treatment of adverse events and cost of switching).
SD = Standard deviation.
Table 5 Utilities for relapse
Definition Mean SD
Base utility while no relapse 0.77 0.12
Tariff at relapse −0.18 0.03
Tariff after 6 months −0.10 0.02
Tariff after 12 months −0.07 0.01
Tariff after 18 months −0.07 0.01
SD = Standard deviation. The SD is used as input for the PSA.
Table 7 Adverse event rates (%)
Adverse eventsa OLAI RLAI
Weight gain 9.0 6.0
Extra-pyramidal symptoms 15.0 25.0
Tardive dyskinesia 0.0 0.0
Somnolence 7.0 5.0
Sexual dysfunction 3.0 3.0
Post-injection syndrome 2.0 0.0
Suicide 0.0 0.0
aAdverse event rates were taken from [14,40,48].
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The model analysis estimated OLAI to be a less costly and
more effective strategy than RLAI based on all studied
base-case parameters. In the base case analysis, OLAI was
both cost reducing and more effective with an incremental
discounted cost savings of €2,940 (SD 300.83) for gains of
0.04 (SD 0.025) LYs and 0.07 (SD 0.019) QALYs with ICER
described as “dominant” for OLAI (i.e. when OLAI dem-
onstrates cost savings and QALY gains versus RLAI it is
described as “dominant” (Table 8)). Over the 5-year time
horizon, OLAI treatment avoided 0.42 (SD 0.049) relapses
per patient compared with RLAI. Treatment with OLAI
resulted in fewer relapses and treatment discontinuations
over the 5-year time horizon (Figure 3). Patients on OLAI
tended to switch treatment less frequently and stayed on
the treatment for approximately 82.5% (SD 0.96%) of the
time compared with about 77.3% (SD 0.98%) for RLAI
over the 5-year period (Figure 4). Base-case economic out-
comes analysis predicts that the OLAI treatment strategy
is less costly and more effective (‘dominant choice’) com-
pared to RLAI. Thus, the model predicted that OLAI is
incrementally cost-effective compared with RLAI. The
ICERs did not vary greatly when using 0% and 6% dis-
count rates compared with the base case 3% discount rate
(Table 8).
Patients who start on RLAI and later switched to
OLAI in the model face the small but non-zero risk of
experiencing post-injection syndrome. In the model,
“switch costs” are accrued to the starting drug, which is
consistent with the intention-to-treat principle. When
the yearly relapse hazard for OLAI is set to equal that for
RLAI, implying absence of any difference in relapse hazardTable 6 Utilities for adverse events
Adverse events Mean Lower CI Upper CI
Extra-pyramidal symptoms −0.054 −0.068 −0.040
Tardive dyskinesia −0.000 −0.023 0.023
Weight gain −0.003 −0.014 0.007
Sedation or drowsiness −0.066 −0.076 −0.056
Sexual dysfunction −0.066 −0.076 −0.056
Post-injection syndrome −0.066 −0.076 −0.056
CI = Confidence interval. The CI is used as input for the PSA.between OLAI and RLAI, the ICERs for OLAI are domin-
ant for both QALY and for relapse avoided ratios.
As the time horizon extended beyond 5 years, the model
showed that OLAI increased the number of QALYs
accrued, decreased the relapse rate, and tended to stabilise
the discounted ICER costs per QALY and per relapse
avoided (Table 8). The dominant character of OLAI
persisted when additional factors were altered.
Sensitivity analyses demonstrated that OLAI remains
dominant and below the acceptable threshold of €30,000
[37] incremental cost per QALY across a wide range of
analyses (Table 8), demonstrating the robustness of the
results. Compared with the base case, OLAI remained
dominant when the utility tariffs were varied (Table 8).
As per the SPC for OLAI [14] a sensitivity analysis was
also run examining the cost effectiveness of a 210 mg/
2 weeks starting dosing (keeping the maintenance dose
equivalent to 300 mg/4 weeks) schedule and was found to
have a negligible impact on the results (see Table 8). Thus,
the dosing schedule as utilised in the model was deemed
representative.
Based on the cost-effectiveness acceptability curve
(CEAC), OLAI is seen as a cost-effective alternative to
RLAI with a probability of 84% at a cost-effectiveness
threshold of €100,000, at 80% for a threshold of €75,000,
and at 72% for a €30,000 threshold (Figure 5). The cost-
effectiveness plane based on net discounted benefit
supports the robustness around analytical and meth-
odological findings for the base case (Figure 6).
Discussion
This is the first pharmacoeconomic model to compare
OLAI with RLAI in the treatment of schizophrenia
within the Spanish healthcare system. The DES model
designed for this study found OLAI dominant within the
societal willingness-to-pay threshold of €30,000 per QALY
[37]. Over the 5-year period, the base case estimated that
OLAI produced an additional 0.07 (SD 0.019) discounted
QALYs gained and 0.04 (SD 0.025) LYs gained per patient
with a dominant discounted incremental cost savings of
€2,940 (SD 300.83) and a dominant ICER per QALY and
per relapse avoided compared with RLAI. The treatment
Table 8 Base case and sensitivity analysis results
OLAI versus RLAI Incremental (discounted) ICER (discounted)
Cost mean (SD) LYs mean (SD) QALYs mean (SD) Relapses mean (SD) Cost/QALY Cost/relapse avoided Cost/life year gained
Base case -€2939.66 (300.83) 0.04 (0.025) 0.07 (0.019) −0.42 (0.049) Dominant Dominant Dominant
Revised OLAI dosing schedule (2 weekly
starting dose & 4 weekly maintenance dose)
-€2810.58 (281.38) 0.04 0.021) 0.07 (0.018) −0.41 (0.046) Dominant Dominant Dominant
Discount Rate set to 0% -€3068.23 (321.06) 0.04 (0.027) 0.08 (0.020) −0.42 (0.049) Dominant Dominant Dominant
Discount rate set to 6% -€981.51 (125.16) 0.0001 (0.000) 0.0005 (0.000) −0.42 (0.049) Dominant Dominant Dominant
Relapse rate of OLAI equal to RLAI (0.176) -€2513.30 (286.30) 0.04 (0.024) 0.05 (0.018) −0.34 (0.044) Dominant Dominant Dominant
Discontinuation of OLAI equal to RLAI (0.445) -€1594.46 (324.59) −0.003 (0.027) −0.003 (0.019) −0.07 (0.050) €472796.00 Dominant €491207.00
Maximum number of switches set to 5 -€2937.57 (314.19) 0.04 (0.023) 0.07 (0.017) −0.42 0.050) Dominant Dominant Dominant
Maximum number of switches set to 10 -€2947.24 (318.27) 0.04 (0.022) 0.07 (0.017) −0.42 (0.052) Dominant Dominant Dominant
Cost of routine management1 increased 30% -€3527.51 (371.13) 0.04 (0.025) 0.07 (0.019) −0.42 (0.049) Dominant Dominant Dominant
Cost of routine management1 decreased 30% -€2351.82 (232.74) 0.04(0.025) 0.07 (0.019) −0.42 (0.049) Dominant Dominant Dominant
Yearly adverse event rate of OLAI equals RLAI -€2878.91 (319.59) 0.04 (0.023) 0.09 (0.016) −0.41 (0.052) Dominant Dominant Dominant
Cost of administration increased 30% -€3083.92 (303.46) 0.04 (0.025) 0.07 (0.019) −0.42 (0.049) Dominant Dominant Dominant
Cost of administration decreased 30% -€2795.41 (298.37) 0.04 (0.025) 0.07 (0.019) −0.42 (0.049) Dominant Dominant Dominant
Cost of administration of OLAI equals RLAI -€3392.17 (301.51) 0.04 (0.025) 0.07 (0.019) −0.42 (0.049) Dominant Dominant Dominant
Time Horizon 1 year -€643.44 (116.98) 0.02 (0.004) 0.02 (0.003) −0.11 (0.023) Dominant Dominant Dominant
Time Horizon 2 years -€1402.48 (168.63) 0.02 (0.009) 0.03 (0.007) −0.21 (0.031) Dominant Dominant Dominant
Time Horizon 3 years -€2005.29 (224.89) 0.02 (0.015) 0.05 (0.011) −0.29 (0.038) Dominant Dominant Dominant
Time Horizon 4 years -€2493.99 (267.06) 0.03 (0.019) 0.06 (0.014) −0.36 (0.044) Dominant Dominant Dominant
Time Horizon 10 years -€4552.43 (513.34) 0.11 (0.057) 0.11 (0.040) −0.72 (0.072) Dominant Dominant Dominant
Time Horizon 15 years -€5491.36 (746.04) 0.19 (0.089) 0.14 (0.059) −0.96 (0.088) Dominant Dominant Dominant
Time Horizon 20 years -€6010.09 (985.99) 0.28 (0.118) 0.16 (0.076 −1.16 (0.111) Dominant Dominant Dominant
Time Horizon 30 years -€6184.28 (1387.21) 0.44 (0.172) 0.20 (0.104) −1.41 (0.144) Dominant Dominant Dominant
Utility tariffs increased 30% -€2939.66 (300.83) 0.04 (0.025) 0.09 (0.024) −0.42 (0.049) Dominant Dominant Dominant
Utility tariffs decreased 30% -€2939.66 (300.83) 0.04 (0.025) 0.05 (0.013) −0.42 (0.049) Dominant Dominant Dominant
Probability of doctors visit for adverse events 5% -€2983.18 (269.74) 0.04 (0.023) 0.07 (0.019) −0.43 (0.044) Dominant Dominant Dominant
Probability of doctors visit for adverse events 15% -€2824.75 (326.69) 0.04 (0.027) 0.07 (0.020) −0.41 (0.050) Dominant Dominant Dominant
Probability of switching treatment following
doctors visit for adverse events 5%
-€2940.17 (303.80) 0.04 (0.024) 0.07 (0.017) −0.42 (0.051) Dominant Dominant Dominant
Probability of switching treatment following
doctors visit for adverse events 25%
-€2849.86 (334.18) 0.04 (0.024) 0.07 (0.018) −0.41 (0.054) Dominant Dominant Dominant
Cost of OLAI increased 25% -€152.19 (302.58) 0.04 (0.025) 0.07 (0.019) −0.42 (0.049) Dominant Dominant Dominant


















Table 8 Base case and sensitivity analysis results (Continued)
Branded drug costs decreased 7.5% -€2899.05 (296.94) 0.04 (0.025) 0.07 (0.019) −0.42 (0.049) Dominant Dominant Dominant
Cost of concomitant medication increased 25% -€2934.53 (302.95) 0.04 (0.025) 0.07 (0.019) −0.42 (0.049) Dominant Dominant Dominant
Cost of concomitant medication decreased 25% -€2944.80 (298.74) 0.04 (0.025) 0.07 (0.019) −0.42 (0.049) Dominant Dominant Dominant
1Including the variables cost of schizophrenia management, inpatient cost of relapse management, outpatient cost of relapse management.





















































Figure 3 Number of relapses and discontinuations per patient over 5 years: OLAI versus RLAI (base case model).
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http://www.biomedcentral.com/1471-244X/14/298continuation rate was higher for OLAI versus RLAI sug-
gesting that OLAI has a better treatment persistence rate
suggesting OLAI might have the potential for a low risk of
discontinuation. The main differences across the two
treatments appear to be linked to the yearly hazards for
relapse and discontinuation, which are lower with OLAI.
Sensitivity analyses using varying discount rates of 0%
and 6%, or varying model time horizons between 1 and
30 years favoured the OLAI treatment strategy. Over a
time horizon of less than 5 years, OLAI had a reduced
QALY advantage but was still dominant. However, as
the time horizon was extended beyond the 5-year mark,
there was a progressive but substantial increase in the
number of QALYs accrued. Concurrently, the annual rate
of relapses per patient decreased. Overall, the estimates
derived by the economic model show that OLAI represents
a cost-effective treatment option compared with RLAI.
The incremental cost per QALY gained with one treat-
ment versus another is widely recognized as an acceptable
payer metric of cost-effectiveness. Overall, from a cost-













Figure 4 Time on treatment: OLAI versus RLAI.in terms of cost/QALY gained, cost/LY gained, and cost/
relapse averted because it was predicted to produce more
QALYs at a lower cost. Factors that make OLAI an alter-
native and cost-effective option versus RLAI in the man-
agement of patients with schizophrenia include higher
QALYs, lower yearly relapse hazard, the lesser probability
of treatment discontinuation, the increase in the number
of QALYs accrued, and the number of relapses averted as
the time horizon was extended. Notwithstanding the
model assumption of a 3-hour post-injection observation
period because of the reported low incidence of post-
injection syndrome, OLAI exhibits a dominant discounted
ICER for cost of administration. This is because RLAI is
administered twice in a month and OLAI only once per
month. Additionally, RLAI therapy requires oral supple-
mentation for the first 3 weeks of therapy [15].
This model has a number of limitations. The most
important limitation concerns the lack of head to head
clinical data for these two therapies. The study design of
the clinical trials for OLAI and RLAI meant that an





Figure 5 OLAI versus RLAI – CEAC.
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the clinical trials adjusted for patient years of exposure
and substantiated with expert clinical opinion.
The model calculations used available data from the
literature and relied upon multiple data sources. Another
limitation of the model is its exclusion of indirect cost
data, which can represent a substantial proportion of the
total costs for the treatment of schizophrenia [12]. Further,
the model assumed the rate of hospitalisation as a proxy
for relapse rates and did not account for the naturalistic
fluctuations in relapse and treatment discontinuation over
time.
Notwithstanding the limitations discussed above, this
model has several strengths. It simulates the real world
treatment processes and environment and provides projec-
tions that should help inform decision-making processes.
An important strength of this model is the dynamic nature
of usual care. The model simulates the real-world environ-
ment that involves switching of treatment, discontinuations,
stopping/restarting treatment. The model assumptions
were substantiated by clinical experts and relied uponFigure 6 Cost-effectiveness plane for OLAI versus RLAI.outputs that are relevant for comparing antipsychotic
drug therapy. Sensitivity analyses helped establish the
validity and robustness of the model findings. This model
can be applied to different time horizons up to a lifetime
permitting projections that demonstrated that as the time-
lines were extended OLAI became increasingly cost-
effective.
Conclusions
The present analysis demonstrated that in the context of
the Spanish healthcare setting OLAI was dominant com-
pared to RLAI. The base case estimates demonstrated that
the OLAI strategy resulted in an additional 0.07 (SD 0.019)
QALYs and 0.04 (SD 0.025) LYs gained per patient. In
addition, patients on OLAI experienced lower number of
relapses and discontinuations per patient over the 5-year
time horizon with cost-savings of €2,940 (SD 300.83).
The lower risks of relapse and discontinuation ensure
that OLAI therapy reduces the cost of patient manage-
ment, lowers the risk of rehospitalisation and associated
costs, and improves the overall cost-effectiveness of OLAI
Dilla et al. BMC Psychiatry 2014, 14:298 Page 11 of 12
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threshold of €30,000 incremental cost per QALY gained.
The lower risks of relapse and discontinuation ensure that
OLAI therapy reduces the cost of patient management,
lowers the risk of rehospitalisation and associated costs
and results in OLAI being cost-effective at a threshold of
€30,000 per QALY in Spain. The results support the use
of OLAI therapy as an alternative to RLAI in patients with
schizophrenia.
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